tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Xoma’s Strategic Acquisitions and Innovative Financial Strategies Drive Buy Rating

Xoma’s Strategic Acquisitions and Innovative Financial Strategies Drive Buy Rating

Leerink Partners analyst David Risinger has maintained their bullish stance on XOMA stock, giving a Buy rating yesterday.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

David Risinger has given his Buy rating due to a combination of factors including Xoma’s strategic acquisition activities and innovative financial strategies. The company has recently announced its acquisition of Mural Oncology, which is part of its broader strategy of engaging in ‘liquidation-as-a-service’ transactions. This approach has been demonstrated in previous deals with Turnstone and HilleVax, potentially bringing in low to mid-single digit millions of dollars per transaction.
Furthermore, Xoma’s acquisition of LAVA Therapeutics to secure royalty rights in partnerships with major players like JNJ and PFE showcases its ability to generate capital and secure future revenue streams through unconventional means. These strategic moves highlight Xoma’s proactive approach to growth and revenue diversification, underpinning Risinger’s confidence in maintaining an Outperform rating for the stock.

According to TipRanks, Risinger is a 5-star analyst with an average return of 9.3% and a 56.71% success rate. Risinger covers the Healthcare sector, focusing on stocks such as Regeneron, Eli Lilly & Co, and Amgen.

In another report released yesterday, H.C. Wainwright also reiterated a Buy rating on the stock with a $104.00 price target.

Disclaimer & DisclosureReport an Issue

1